Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487598 | 0.83 | BRD4 (0.61) | BRD4MEN1KMT2ARXFP1HTR6 | |
| SCHEMBL2180777 | 0.82 | PTPN11 (0.41) | BRD4RAB9AHPGDNPC1MEN1 | |
| SCHEMBL1082937 | 0.80 | BRD4 (0.54) | BRD4RAB9AHPGDNPC1MEN1 | |
| SCHEMBL2179100 | 0.78 | BRD4 (0.54) | BRD4RAB9ANPC1KMT2AMAPT | |
| SCHEMBL1584935 | 0.77 | BRD4 (0.51) | BRD4MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1050312 | 0.76 | BRD4 (0.64) | BRD4HTR6PTPN11SMN1; SMN2LMNA | |
| SCHEMBL1049641 | 0.76 | BRD4 (0.56) | BRD4HTR6SMN1; SMN2LMNA | |
| SCHEMBL20292849 | 0.76 | PTPN11 (0.52) | BRD4RAB9APTPN11POLBHTT | |
| SCHEMBL8321863 | 0.75 | BRD4 (0.61) | BRD4RAB9ANPC1RXFP1HTR6 | |
| SCHEMBL12410829 | 0.75 | HPGD (0.40) | RAB9AHPGDNPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166173-A1 | 3,5-DISUBSTUTUTED 1H-PYRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS | EISAI CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
| EP-1720871-B1 | 3,5-DISUBSTITUTED 1H-PYRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2010-05-19 | — | — | EP | disclosed |
| EP-1720871-B1 | 3,5-DISUBSTITUTED 1H-PYRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2010-05-19 | — | — | EP | disclosed |
| EP-1720871-A1 | 3,5-DISUBSTITUTED 1H-PYRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS | Eisai London Research Laboratories Limited (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085244-A1 | 3,5-DISUBSTITUTED 1H-PZRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS | EISAI LONDON RESEARCH LABORATORIES LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005085244-A1 | 3,5-DISUBSTITUTED 1H-PZRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS | EISAI LONDON RESEARCH LABORATORIES LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166173-A1 | 3,5-DISUBSTUTUTED 1H-PYRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS | API5, CDK5, MAPKAPK5 | BRD4 535/4885RAB9A 2873/4885HPGD 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.